Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director

Regulations by 2FIRSTS, edited by Sophia
May.06.2024
Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Recent announcements from Jinjia Corporation (002191) reveal lifted restrictions on Qiao Luyu but investigation and detention of Li Dehua.

Recently, listed company Jinjia Group (002191) on the Shenzhen Stock Exchange has issued a series of announcements. Firstly, the disciplinary commission in Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Secondly, the company's director and deputy general manager, Li Dehua, has been placed under investigation and detained.

 

According to relevant documents issued by the Supervision Committee of Enyang District, Bazhong City, the actual controller and chairman of the company, Qiao Luyu, is under investigation and has been placed under detention. On April 27, 2024, the company received a notice from the Supervision Committee of Enyang District, Bazhong City, lifting the detention of Qiao Luyu (Enjianjie Lutong [2024] No. 2), indicating that the Supervision Committee of Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Currently, Qiao Luyu is able to carry out his duties as the chairman and legal representative of the company as normal, and the company's director and general manager, Hou Xudong, no longer acts on behalf of the company's chairman and legal representative.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image source: Jincare Group

 

On May 1st, the company received a notification from the Jinzhou District Supervisory Committee in Dalian City regarding the investigation and detention of the company's director and deputy general manager, Li Dehua.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image Source: Jincar Group

 

Jiangjia Group stated that the company has a sound governance structure and internal control mechanism, operating in compliance with laws, regulations, and rules such as the Company Law, the Shenzhen Stock Exchange Listing Rules, the Corporate Governance Guidelines for Listed Companies, and the company's articles of association. The company has already made proper arrangements for the work related to Li Dehua, and the ongoing investigation will not have a significant impact on the company's daily operations. All production and operational activities of the company are proceeding as usual.

 

Jinjia Corporation stated that as of the date of this announcement, the company is not aware of the progress and conclusion of the investigation. The company will continue to monitor the developments of the investigation and adhere to relevant laws and regulations, fulfill its disclosure obligations in a timely manner, and alert of any related risks.

 

According to the 2023 annual report of Jinjia Group, Li Dehua was born in 1968, is of Chinese nationality, does not have permanent residency abroad, has a high school education, and has been employed by Jinjia Group since 1996. He currently serves as a director, executive deputy general manager, and general manager of the production and marketing branch of the company, as well as holding other positions such as executive director of Shenzhen Qianhai Blueberry Culture Communication Co., Ltd. In 2023, Li Dehua received a total pre-tax compensation of 2.361 million yuan from the company.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
Breaking News | FDA Adds on! Plus Nicotine Pouches to PMTA-Authorized List
The U.S. Food and Drug Administration (FDA) has added ON! Plus nicotine pouch products to its list of authorized products, disclosing that the brand has received Marketing Granted Orders (MGO) through the Premarket Tobacco Product Application (PMTA) pathway. The update makes on! Plus the second nicotine pouch brand authorized via PMTA, following ZYN. As of publication, the FDA had not issued a separate press release on the decision.
News
Dec.20
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
EVO NXT will move to Prague in April 2026. As an event’s official media partner for four consecutive years, 2Firsts recently interviewed the organisers, who said the relocation reflects strong growth in Eastern European markets for alternative nicotine products. They described EVO NXT as not a traditional trade fair but a business festival shaped by rapid changes in regulation, markets and technological innovation across the global nicotine industry.
Feb.03
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
The vaping brand OXBAR has recently listed its open-system, refillable pod device OX35K on its official website. The product features a “2ml built-in pod + two 10ml external refill bottles” e-liquid supply structure and supports top refilling, with a claimed puff count of up to 35,000. It is equipped with a 1000mAh built-in battery and offers dual power modes—BOOST and ECO—positioning the device to balance high-puff performance with an open-system form factor.
Jan.13 by 2FIRSTS.ai
Azerbaijan Imposes Comprehensive E-Cigarette Ban Covering Import, Export, Sales and Use, Effective April 1
Azerbaijan Imposes Comprehensive E-Cigarette Ban Covering Import, Export, Sales and Use, Effective April 1
Azerbaijan has approved amendments to its tobacco law that introduce a comprehensive ban on e-cigarettes and their components, covering import, export, production, storage, wholesale and retail sales, and use. Nicotine-containing e-cigarettes are classified as tobacco products under the revised framework. The law takes effect on April 1, 2026.
Jan.27 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
China Caps E-Cigarette Capacity and Requires Export Compliance Proof to Curb “Involution”
China Caps E-Cigarette Capacity and Requires Export Compliance Proof to Curb “Involution”
China’s top tobacco regulator has issued a directive aimed at preventing excess capacity and curbing “involution-style” competition in the e-cigarette sector. The notice tightens investment controls, formalizes verified capacity management and requires exporters to submit compliance proof for destination markets, signaling a push toward higher industry concentration and stricter cross-border oversight.
Special Report
Feb.13